Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Employer
- ;
- International Institute of Molecular and Cell Biology in Warsaw
- RMIT University
- Biobizkaia Health Research Institute
- Duke University
- Radboud University Medical Center (Radboudumc)
- University of Louisville
- University of Oslo
- Uppsala University
- ; University of Warwick
- Academic Europe
- Ilya Pharma
- Institute of Physical Chemistry, Polish Academy of Sciences
- Johannes Gutenberg University Mainz •
- Karolinska Institutet
- Leibniz
- Linköping University
- Stockholm University
- TRON – Translationale Oncology Oncology at the University Medical Center of the Johannes Gutenberg University Mainz •
- Technical University of Munich
- University Medical Centre Groningen (UMCG)
- University of Basel
- University of British Columbia
- University of Florida
- University of Massachusetts Medical School
- University of Pittsburgh
- Université de Caen Normandie
- 17 more »
- « less
-
Field
-
. As a PhD candidate you will focus on analyses of patient-related factors for outcome and chemotherapy and immunotherapy treatment response and toxicity in bladder cancer. The candidate will contribute
-
biomarkers for precise disease monitoring. Furthermore, the unique glycan profiles of tumors provide appealing targets for cancer immunotherapy. This project seeks to exploit tumor-specific glycosylation
-
position within a Research Infrastructure? No Offer Description The LIT - Leibniz Institute for Immunotherapy (foundation under civil law) (www.lit.eu ) is a biomedical research center focusing on
-
research training and experience in cellular immunology and tumor immunotherapy study. Previous training in immunology or biochemistry and experience with human subject study is essential. Techniques
-
for a motivated Senior Research Assistant with expertise and knowledge in cancer immunotherapy and genetic engineering of (immune) cells. Join our exciting CAR-NK therapy program and translational
-
. The position is part of the project entitled “Spatial Determinants of Immunotherapy Resistance in Cancer”, funded by the NCN (National Science Centre) in cooperation with the SNSF (Swiss National Science
-
University of Massachusetts Medical School | Worcester, Massachusetts | United States | 2 months ago
platforms for these biologics are local delivery to the mucosal tissue. This includes passive immunotherapy as well as future development of genetic delivery of the biologics. This project provides
-
of Medicine is seeking a highly motivated scientist to develop immunotherapy strategies for neurological diseases and to identify novel genes that cause neurological diseases development. The candidate will
-
such as immunotherapies are revolutionising cancer treatment. However, as they are not effective in all patients they should be tailored to the right patients while work to identify new drug targets and
-
compounds, cancer or immunotherapy research. The candidate should be familiar with air-sensitive chemistry and general analytical techniques such as FTIR, NMR, electrochemistry, etc. Desirable criteria